Pennant Capital Management’s Gilead Sciences GILD Stock Holding History

Pennant Capital Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-2,141,000	Closed	-$202M	–	43
2014 Q4	$202M	Buy	2,141,000 +280,000	+15%	+$29M	3.79%	11
2014 Q3	$198M	Sell	1,861,000 -209,000	-10%	-$20.5M	3.47%	14
2014 Q2	$172M	Buy	+2,070,000	New	+$161M	3.07%	15

Other funds holding GILD

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Pennant Capital Management's GILD Position: Q1 2015 in Review

Pennant Capital Management sold out of Gilead Sciences (GILD) in Q1 2015, closing a stake of 2,141,000 shares — an estimated $202M sold.

Pennant Capital Management first reported a position in GILD in Q2 2014 and held it in 3 quarters. The position peaked at $202M in Q4 2014. 1,492 funds tracked by Wall St. Rank hold GILD as of Q1 2015.

Pennant Capital Management reported no remaining Gilead Sciences position as of Q1 2015 after selling out during the quarter.
Pennant Capital Management sold 2,141,000 Gilead Sciences shares in Q1 2015, an estimated $202M.
Pennant Capital Management first reported a position in Gilead Sciences in Q2 2014 and held it in 3 quarters.
Pennant Capital Management's Gilead Sciences position peaked at $202M in Q4 2014.
1,492 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2015.

Based on Pennant Capital Management's 13F filing for Q1 2015, filed 15 May 2015.